{"id":"CHEMBL10878","canonicalSmiles":"COc1ccc2cccc(CCNC(C)=O)c2c1","inchiKey":"YJYPHIXNFHFHND-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AGOMELATINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Valdoxan"],"synonyms":["Agomelatine","S-20098","S20098","Thymanax"],"crossReferences":{"PubChem":["170466417","174006904"],"Wikipedia":["Agomelatine"],"drugbank":["DB06594"]},"linkedTargets":{"rows":["ENSG00000168412","ENSG00000134640","ENSG00000147246"],"count":3},"linkedDiseases":{"rows":["MONDO_0005090","MONDO_0002050","MONDO_0002009","HP_0000726","EFO_0003761","EFO_0004242","EFO_0005230"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for unipolar depression and depressive disorder and has 5 investigational indications."}
{"id":"CHEMBL114551","canonicalSmiles":"CC(=N)NCCSCC[C@H](N)C(=O)O","inchiKey":"MOLOJNHYNHBPCW-ZETCQYMHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GW-274150","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GW274150","Gw-274150"],"crossReferences":{"drugbank":["DB12237"]},"linkedTargets":{"rows":["ENSG00000007171"],"count":1},"linkedDiseases":{"rows":["MONDO_0005277","EFO_0000685","MONDO_0004979"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL114655","canonicalSmiles":"CC(CCc1ccccc1)NC(C)C(O)c1ccc(O)cc1","inchiKey":"PTGXAUBQBSGPKF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NYLIDRIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Buphenin","Buphenine","Nylidrin"],"crossReferences":{"PubChem":["104171196","144203755","170465637","26752307","90340605"],"Wikipedia":["Buphenine"],"drugbank":["DB06152"]},"childChemblIds":["CHEMBL1204337"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL118841","canonicalSmiles":"COc1ccc2c(c1)-c1nn(CCCN(C)C)c3ccc([N+](=O)[O-])c(c13)N2","inchiKey":"HZCWPKGYTCJSEB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PYRAZOLOACRIDINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-366140","NSC-627168","PD 115934","PD-115934","Pyrazoloacridine"],"crossReferences":{"PubChem":["493329"],"drugbank":["DB12549"]},"childChemblIds":["CHEMBL141769"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL1197564","canonicalSmiles":"O=C1Cc2ccccc2C(=C2CCNCC2)c2ccsc21","inchiKey":"IYSYPCSSDZBWHN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NORKETOTIFEN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["N-desmethylketotifen","Norketotifen"],"childChemblIds":["CHEMBL576725"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1200514","canonicalSmiles":"CN(CCCCCCCCCCN(C)C(=O)Oc1cccc([N+](C)(C)C)c1)C(=O)Oc1cccc([N+](C)(C)C)c1.[Br-].[Br-]","inchiKey":"YHKBUDZECQDYBR-UHFFFAOYSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"DEMECARIUM BROMIDE","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1201229","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Humorsol","Tosmilen"],"synonyms":["BC-48","Demecarium bromide","Demekastigmine bromide"],"crossReferences":{"PubChem":["57265778"],"Wikipedia":["Demecarium_bromide"],"chEBI":["4391"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1959."}
{"id":"CHEMBL1200550","canonicalSmiles":"O=P(O)(O)O.c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1","inchiKey":"DUIGUKRYYAGJAF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ANTAZOLINE PHOSPHATE","yearOfFirstApproval":1994,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1305","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Antazoline phosphate","NSC-755865"],"crossReferences":{"PubChem":["26747864","26747865","50107311","56422487","855846"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1994."}
{"id":"CHEMBL1200606","canonicalSmiles":"Cc1cccc(C)c1OCC(C)N.Cl","inchiKey":"NFEIBWMZVIVJLQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MEXILETINE HYDROCHLORIDE","yearOfFirstApproval":1985,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL558","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Mexiletine hydrochloride","Mexitil","Mexitil p.l."],"synonyms":["KO 1173 CL","KO-1173","KO-1173 CL","KO-1173-CL","Katen","Mexiletine hcl","Mexiletine hydrochloride","NSC-758639"],"crossReferences":{"DailyMed":["mexiletine%20hydrochloride"],"PubChem":["144204800","144204801","170464740","26732616","26747574","50106611"],"chEBI":["6917"]},"linkedTargets":{"rows":["ENSG00000185313","ENSG00000153253","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000136531","ENSG00000007314","ENSG00000196876"],"count":10},"linkedDiseases":{"rows":["HP_0004308","EFO_0009387"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and is indicated for ventricular arrhythmia and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200890","canonicalSmiles":"COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl","inchiKey":"MUZQPDBAOYKNLO-RKXJKUSZSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"OXYCODONE HYDROCHLORIDE","yearOfFirstApproval":1950,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL656","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"]},"tradeNames":["Abtard","Candox","Carexil","Dolocodon pr","Leveraxo","Longtec","Lynlor","Oxaydo","Oxecta","Oxeltra","Oxycodone hydrochloride","Oxycontin","Oxylan","Oxynorm","Reltebon","Roxicodone","Roxybond","Shortec","Zomestine"],"synonyms":["Endocodone","Oxecta","Oxycodone hcl","Oxycodone hydrochloride","Oxycodone hydrochloride cii"],"crossReferences":{"DailyMed":["oxycodone%20hydrochloride"],"chEBI":["7859"]},"linkedTargets":{"rows":["ENSG00000112038"],"count":1},"linkedDiseases":{"rows":["EFO_0003931","HP_0012532","EFO_1000786","EFO_0004616","HP_0003419","EFO_0003843","EFO_0000311"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1950 and is indicated for chronic pain and pain and has 3 investigational indications. It was withdrawn in United States. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201141","canonicalSmiles":"CC(C)Cc1ccc(C(C)C(=O)O)cc1.NCCCC[C@H](N)C(=O)O","inchiKey":"IHHXIUAEPKVVII-ZSCHJXSPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IBUPROFEN LYSINE","yearOfFirstApproval":2006,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL521","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Feminax express","Ibuprofen lysine","Neoprofen","Nurofen advance","Nurofen max strgth mig pain","Nurofen migraine pain","Nurofen tension headache"],"synonyms":["Arfen","Dolormin","Ibuprofen l-lysine","Ibuprofen lysinate","Ibuprofen lysine","Imbun","Lisiprofen","Saren","Solufenum","Soluphene"],"crossReferences":{"DailyMed":["ibuprofen%20lysine"]},"linkedTargets":{"rows":["ENSG00000073756","ENSG00000095303"],"count":2},"linkedDiseases":{"rows":["HP_0001643"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2006 and is indicated for patent ductus arteriosus."}
{"id":"CHEMBL1201142","canonicalSmiles":"C#CCN[C@@H]1CCc2ccccc21.CS(=O)(=O)O","inchiKey":"JDBJJCWRXSVHOQ-UTONKHPSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RASAGILINE MESYLATE","yearOfFirstApproval":2006,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL887","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Azilect","Rasagiline mesylate"],"synonyms":["Agilect","Azilect","Rasagiline (as mesilate)","Rasagiline mesilate","Rasagiline mesylate","Rasagline ratiopharm","TVP-1012"],"crossReferences":{"DailyMed":["rasagiline%20mesylate"],"PubChem":["144206188","170465410"]},"linkedTargets":{"rows":["ENSG00000069535"],"count":1},"linkedDiseases":{"rows":["EFO_1001050","MONDO_0005180"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2006 and is indicated for parkinson disease and has 1 investigational indication."}
{"id":"CHEMBL1201362","canonicalSmiles":"C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl","inchiKey":"FCSHDIVRCWTZOX-DVTGEIKXSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CLOBETASOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Clobetasol"],"crossReferences":{"PubChem":["144206935"],"drugbank":["DB11750"],"chEBI":["205919"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1201529","drugType":"Unknown","blackBoxWarning":false,"name":"TECHNETIUM TC 99M SULFUR COLLOID","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["An-sulfur colloid","An-sulfur colloid kit","Technecoll","Technescan sulfur colloid","Technetium tc 99m sulfur colloid","Technetium tc 99m tsc","Tesuloid"],"synonyms":["99mtc-labeled sulfur colloid","Tc99m-sulfur colloid","Technetium (99mtc) sulfur colloid","Technetium tc 99m sulfur colloid","Technetium tc-99m sulfur colloid","Technetium tc-99m sulfur colloid kit"],"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 1 investigational indication."}
{"id":"CHEMBL1201557","drugType":"Protein","blackBoxWarning":true,"name":"INTERFERON ALFACON-1","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Infergen"],"synonyms":["Interferon alfacon-1","Rsifn-co"],"linkedTargets":{"rows":["ENSG00000159110","ENSG00000142166"],"count":2},"linkedDiseases":{"rows":["EFO_0004220","EFO_0007328","EFO_0003047"],"count":3},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201571","drugType":"Protein","blackBoxWarning":false,"name":"ALEFACEPT","yearOfFirstApproval":2003,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Amevive"],"synonyms":["Alefacept","BG-9273","BG-9712","BG9273","BG9712","Human lfa-3igg fusion protein","LFA-3CD2","LFA-3TIP","LFA3TIP"],"crossReferences":{"DrugCentral":["5088"],"Wikipedia":["Alefacept"]},"linkedTargets":{"rows":["ENSG00000116824"],"count":1},"linkedDiseases":{"rows":["MONDO_0013730","Orphanet_2897","MONDO_0005147","EFO_0000676","EFO_0000574","EFO_0003778","EFO_0000274","HP_0001915","Orphanet_163927","EFO_1000726","EFO_0000540","EFO_1002048"],"count":12},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and is indicated for immune system disease and has 9 investigational indications."}
{"id":"CHEMBL1201619","drugType":"Unknown","blackBoxWarning":false,"name":"APROTININ","yearOfFirstApproval":1993,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"year":2007},"tradeNames":["Trasylol"],"synonyms":["Aprotinin","Aprotinin (bovine)","Aprotinin (synthetic)","Aprotinin biosynthetic","Aprotinin bovine","Aprotinin concentrated solution","BAYER A 128","BAYER-A-128","BAYERA-128","Bovine aprotinin","Fibrinolysis inhibitor","RIKER 52G","RIKER-52G","RP 9921","RP-9921"],"crossReferences":{"DrugCentral":["4839"],"Wikipedia":["Aprotinin"]},"linkedTargets":{"rows":["ENSG00000122194","ENSG00000164344"],"count":2},"linkedDiseases":{"rows":["MP_0001914","EFO_0000278","MONDO_0007254"],"count":3},"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1993 and is indicated for hemorrhage and has 2 investigational indications. It was withdrawn in United States  in 2007."}
{"id":"CHEMBL1201657","drugType":"Oligosaccharide","blackBoxWarning":false,"name":"HEPARIN SODIUM","yearOfFirstApproval":1939,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Heparin lock flush","Heparin sodium","Heparin sodium preservative free","Lipo-hepin","Liquaemin lock flush","Liquaemin sodium","Liquaemin sodium preservative free","Multiparin","Panheprin","Pump-hep","Sodium heparin","Thrombophob","Unihep","Uniparin","Uniparin fte"],"synonyms":["Crude heparin","Crude heparin porcine","Heparin sodium","Heparin sodium porcine","Heparin sodium unfractionated","Heparin sodium, porcine","Heparinum natricum","Liquemin sodium","S01XA14","Sodium heparin"],"crossReferences":{"DailyMed":["heparin%20sodium"]},"linkedTargets":{"rows":["ENSG00000117601"],"count":1},"linkedDiseases":{"rows":["MONDO_0002492","EFO_0003777","EFO_0011061","EFO_0000365","EFO_0000275","EFO_0000266","EFO_1001129","EFO_1001951","EFO_0003913","EFO_0003964","EFO_0003103","EFO_0000771","EFO_0008585","EFO_0000544","HP_0004420","EFO_0003884","EFO_0000400","EFO_1000059","EFO_1001904","EFO_0009686","HP_0002619","EFO_1001395","HP_0001919","EFO_0004286","EFO_0009516","HP_0001873","HP_0100806","MP_0001914","EFO_0000546","HP_0031364","MONDO_0100096","MONDO_0000831","MONDO_0002243","EFO_0003907","EFO_0003033","HP_0031273","EFO_0000668","EFO_0005672","HP_0004418","EFO_0004214","EFO_0006834","EFO_0008507","EFO_1000637","MONDO_0020673","EFO_1002048","EFO_0002950","EFO_0003966","HP_0000083","EFO_1001480","EFO_1001375","EFO_0000712","HP_0004419","HP_0004936","EFO_0000694","EFO_0000616","EFO_0000545","HP_0002140","EFO_0001645","MONDO_0000870","EFO_0009315","EFO_0000319","EFO_0001073","EFO_0000311","EFO_0003106","HP_0001907","EFO_0000713","EFO_1000985","EFO_0010680","MONDO_0021148","EFO_0003827","MONDO_0005147","EFO_0008583","EFO_0000612","MONDO_0005148","MONDO_0005178"],"count":75},"description":"Oligosaccharide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1939 and has 9 approved and 48 investigational indications."}
{"id":"CHEMBL1229535","canonicalSmiles":"CC(=O)/N=c1/[nH]c(C)c(-c2ccc(Cl)c(S(=O)(=O)NCCO)c2)s1","inchiKey":"JFVNFXCESCXMBC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1229535","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06836"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1231334","canonicalSmiles":"OCCCCCCBr","inchiKey":"FCMCSZXRVWDVAW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1231334","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04637"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1232076","canonicalSmiles":"c1cc(SSc2ccncc2)ccn1","inchiKey":"UHBAPGWWRFVTFS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"4,4'-Dithiodipyridine","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4,4'-Dithiodipyridine"],"crossReferences":{"PubChem":["49647666"],"drugbank":["DB07623"],"chEBI":["41814"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1232801","canonicalSmiles":"Nc1nc(=O)c2c([nH]1)NC[C@@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O","inchiKey":"VVIAGPKUTFNRDU-OLZOCXBDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FOLINIC ACID","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Folinic acid"],"crossReferences":{"drugbank":["DB03256"]},"childChemblIds":["CHEMBL1554710"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 24 investigational indications."}
{"id":"CHEMBL1232829","canonicalSmiles":"CCc1oc2cc(S(=O)(=O)Nc3ccc(S(=O)(=O)Nc4nccs4)cc3)ccc2c1C(=O)c1cc(Br)c(O)c(Br)c1","inchiKey":"SXKBTDJJEQQEGE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1232829","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03311"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1234101","canonicalSmiles":"Cc1cc2nc3[nH]c(=O)[nH]c(=O)c3nc2cc1C","inchiKey":"ZJTJUVIJVLLGSP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LUMICHROME","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04345"],"chEBI":["17781"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1235146","canonicalSmiles":"c1ccc(-c2ccc(Cn3ccnc3)cc2)cc1","inchiKey":"DLYMRVCQTVOYEW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1235146","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08369"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1269025","canonicalSmiles":"CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1","inchiKey":"HGVDHZBSSITLCT-JLJPHGGASA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"EDOXABAN","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Lixiana"],"synonyms":["DU-176","Edoxaban"],"crossReferences":{"DailyMed":["edoxaban%20tosylate"],"drugbank":["DB09075"],"chEBI":["85973"]},"childChemblIds":["CHEMBL3542264","CHEMBL2105682"],"linkedTargets":{"rows":["ENSG00000126218"],"count":1},"linkedDiseases":{"rows":["EFO_0000694","EFO_0003777","HP_0002140","EFO_0000275","EFO_0001645","EFO_0004286","EFO_0000266","MP_0001914","MONDO_0100096","MONDO_0000831","EFO_0003827","EFO_0000712","EFO_0003907","EFO_0000612","HP_0004419","EFO_0009314","EFO_0000400","EFO_0004265"],"count":18},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and has 5 approved and 12 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1364","canonicalSmiles":"Cc1ncc(CO)c(CO)c1O","inchiKey":"LXNHXLLTXMVWPM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PYRIDOXINE","yearOfFirstApproval":1985,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Adermine","Hexa-Betalin","Hexabione","M.V.I.-12","NSC-759148","Pyridoxine","Pyridoxine (vit b6)","Pyridoxol","Vitamin B6","Vitamin b-6","Vitamin v6"],"crossReferences":{"DailyMed":["pyridoxine%20hydrochloride"],"PubChem":["11112145","144207193","144210683","170464634"],"Wikipedia":["Pyridoxine"],"drugbank":["DB00165"],"chEBI":["16709"]},"childChemblIds":["CHEMBL1200756"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 8 approved and 21 investigational indications."}
{"id":"CHEMBL144366","canonicalSmiles":"O=C1CCc2cccc3c2N1CC3","inchiKey":"XRJLAOUDSILTFT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PYROQUILON","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["29217954"],"drugbank":["DB02756"],"chEBI":["45141"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL157265","canonicalSmiles":"O=[N+]([O-])c1ccc(O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)cc1","inchiKey":"IFBHRQDFSNCLOZ-YBXAARCKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL157265","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02632"],"chEBI":["355715"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1593874","canonicalSmiles":"CC(=O)Oc1cccc(O)c1","inchiKey":"ZZPKZRHERLGEKA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RESORCINOL MONOACETATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Euresol"],"synonyms":["Resorcin acetate","Resorcinol monoacetate"],"crossReferences":{"PubChem":["144204959","170465513","26748806"],"drugbank":["DB15480"],"chEBI":["29672"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL160347","canonicalSmiles":"COc1cc(Br)c2oc(C3CCNCC3)cc2c1","inchiKey":"WZXHSWVDAYOFPE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BROFAROMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Brofaromine","Consonar"],"crossReferences":{"Wikipedia":["Brofaromine"],"drugbank":["DB13876"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1705","canonicalSmiles":"Cl.Clc1cccc(Cl)c1NC1=NCCN1","inchiKey":"ZNIFSRGNXRYGHF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"CLONIDINE HYDROCHLORIDE","yearOfFirstApproval":1974,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL134","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Catapres","Catapres p.l.","Catapres tts 1","Catapres tts 2","Catapres tts 3","Clonidine hydrochloride","Dixarit","Duraclon","Jenloga","Kapvay"],"synonyms":["Clonidine hcl","Clonidine hydrochloride","Dichloranilino imidazolin","NSC-756699","ST-155"],"crossReferences":{"DailyMed":["clonidine%20hydrochloride"],"PubChem":["144211869","26719783","50106022"]},"linkedTargets":{"rows":["ENSG00000274286","ENSG00000184160","ENSG00000150594"],"count":3},"linkedDiseases":{"rows":["EFO_0003888","EFO_0003777","EFO_0003843","EFO_0000537"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1974 and is indicated for attention deficit hyperactivity disorder and hypertension and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1742990","drugType":"Protein","blackBoxWarning":true,"name":"BELATACEPT","yearOfFirstApproval":2011,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Nujolix","Nulojix"],"synonyms":["BMS-224818","Belatacept","LEA29Y"],"crossReferences":{"DailyMed":["belatacept"],"DrugCentral":["5091"]},"linkedTargets":{"rows":["ENSG00000121594","ENSG00000114013"],"count":2},"linkedDiseases":{"rows":["EFO_0000685","HP_0000093","MONDO_0005147","EFO_0003884","EFO_0000540","EFO_0000400","EFO_0004599","EFO_1002048","EFO_0011056"],"count":9},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for immune system disease and has 5 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL176058","canonicalSmiles":"CC(C)CCn1c(=O)c(C2=NS(=O)(=O)c3ccccc3N2)c(O)c2ccccc21","inchiKey":"MQFPIRFODWNQIO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL176058","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07275"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1788389","drugType":"Small molecule","blackBoxWarning":false,"name":"STIBOPHEN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Fuadin"],"synonyms":["Corystibin","Fantorin","Fouadin","Neoantimosan","Pyrostib","Repodral","SDT-91","Stibofen","Stibophen","Stibophen heptahydrate","Trimon"],"crossReferences":{"DrugCentral":["4712"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL184999","canonicalSmiles":"CC(C)OC(=O)CCC/C=C\\CC[C@H]1[C@@H](O)CO[C@@H]1/C=C/[C@@H](O)COc1cccc(Cl)c1","inchiKey":"SGNMBLPAWMQIHK-LYTYUWFYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AL-12182","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AL-12182","Al-12182"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL185073","canonicalSmiles":"CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1[N+]1(C)CCCCC1","inchiKey":"GVEAYVLWDAFXET-XGHATYIMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PANCURONIUM","yearOfFirstApproval":1972,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Pancuronium","Pavulon"],"crossReferences":{"DailyMed":["pancuronium%20bromide"],"PubChem":["50104094","90341747"],"Wikipedia":["Pancuronium_bromide"],"drugbank":["DB01337"],"chEBI":["7907"]},"childChemblIds":["CHEMBL1200757"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1972."}
{"id":"CHEMBL1863513","canonicalSmiles":"C/C=C(/C)C(=O)O[C@H]1C(C)=C[C@]23C(=O)[C@@H](C=C(CO)[C@@H](O)[C@]12O)[C@H]1[C@@H](C[C@H]3C)C1(C)C","inchiKey":"VDJHFHXMUKFKET-WDUFCVPESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"INGENOL MEBUTATE","yearOfFirstApproval":2010,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Picato"],"synonyms":["AGN 204332","Ingenol mebutate","PEP-005","PEP005"],"crossReferences":{"DailyMed":["ingenol%20mebutate"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for actinic keratosis and has 11 investigational indications."}
{"id":"CHEMBL190461","canonicalSmiles":"C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O","inchiKey":"QHMBSVQNZZTUGM-ZWKOTPCHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CANNABIDIOL","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Epidiolex"],"synonyms":["(-)-cannabidiol","(-)-cbd","(-)-trans-cannabidiol",".delta.1(2)-trans-cannabidiol","BTX-1204","BTX-1503","CBD","Cannabidiol","Cannabidiol solution","GWP-42003","GWP-42003-P","GWP42003","GWP42003-P"],"crossReferences":{"DailyMed":["cannabidiol"],"drugbank":["DB09061"],"chEBI":["69478"]},"linkedTargets":{"rows":["ENSG00000118432"],"count":1},"linkedDiseases":{"rows":["HP_0001397","EFO_0000729","EFO_0002610","MONDO_0002959","EFO_0003768","Orphanet_778","MONDO_0100062","HP_0100543","EFO_1000634","MONDO_0008903","EFO_0004616","EFO_1000789","MONDO_0004976","EFO_0008526","MONDO_0013730","EFO_0003756","EFO_0005762","EFO_0003782","HP_0012532","EFO_0010072","EFO_0000180","EFO_0003758","Orphanet_2382","EFO_0000384","Orphanet_399","MP_0001845","MONDO_0100096","EFO_0003108","HP_0001249","EFO_0009878","MONDO_0005090","EFO_0005687","EFO_0008507","MONDO_0007254","EFO_0003778","EFO_0008568","EFO_0007191","HP_0002829","MONDO_0005277","EFO_0005676","EFO_1000783","EFO_0000474","EFO_0000289","Orphanet_739","Orphanet_3451","EFO_0003100","EFO_0003144","MONDO_0005180","EFO_0000673","EFO_0009854","MONDO_0007079","EFO_0004242","EFO_0005230","EFO_0004215","EFO_0000616","Orphanet_93955","HP_0011147","EFO_0000677","EFO_0005407","EFO_0001358","HP_0001250","EFO_0010702","Orphanet_64280","EFO_0003843","EFO_0004599","Orphanet_3205","Orphanet_908","EFO_0003890","Orphanet_33069","EFO_0004895","EFO_0000764","EFO_0005611","EFO_0005411","EFO_0003944","MONDO_0005178"],"count":75},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and has 5 approved and 55 investigational indications."}
{"id":"CHEMBL1908362","drugType":"Small molecule","blackBoxWarning":true,"name":"GADOFOSVESET TRISODIUM","yearOfFirstApproval":2008,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1908843","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ablavar","Vasovist"],"synonyms":["Gadofosveset trisodium","MS 32520","MS-32520","Vasovist"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2008. This drug has a black box warning from the FDA."}
{"id":"CHEMBL193676","canonicalSmiles":"CC1=CC[C@]2(CO)CO[C@H](c3ccc(O)cc3)[C@H]1C2","inchiKey":"XXIFNRNIQJKFLP-XHSDSOJGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL193676","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07086"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2028665","canonicalSmiles":"CCOC(=O)OC[C@H]1O[C@@H](Oc2nn(C(C)C)c(C)c2Cc2ccc(OC(C)C)cc2)[C@H](O)[C@@H](O)[C@@H]1O","inchiKey":"UAOCLDQAQNNEAX-ABMICEGHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"REMOGLIFLOZIN ETABONATE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GSK-189075","GSK-189075A","GSK189075A","Remogliflozin etabonate"],"crossReferences":{"drugbank":["DB12935"]},"linkedTargets":{"rows":["ENSG00000140675"],"count":1},"linkedDiseases":{"rows":["MONDO_0005148"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL205596","canonicalSmiles":"C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O","inchiKey":"BHQCQFFYRZLCQQ-OELDTZBJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHOLIC ACID","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cholbam","Kolbam","Orphacol"],"synonyms":["Cholalic acid","Cholic Acid","Cholic acid","E1000","NSC-6135"],"crossReferences":{"DailyMed":["cholic%20acid"],"PubChem":["26754161","26754162"],"Wikipedia":["Cholic_acid"],"drugbank":["DB02659"],"chEBI":["16359"]},"childChemblIds":["CHEMBL1421383","CHEMBL1334097","CHEMBL3187726"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for peroxisomal disease and liver disease and has 10 investigational indications."}
{"id":"CHEMBL2103864","canonicalSmiles":"CC[C@@H](Nc1c(Nc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1.O","inchiKey":"AFTCWZSEWTXWTL-BTQNPOSSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NAVARIXIN","maximumClinicalTrialPhase":2,"parentId":"CHEMBL216981","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mk-7123","Navarixin","Navarixin monohydrate","PS291822","SCH 527123","SCH527123"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL2103875","canonicalSmiles":"CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1","inchiKey":"LIRYPHYGHXZJBZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRAMETINIB","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Mekinist"],"synonyms":["GSK-1120212","GSK1120212","JTP 74057","JTP-74057","TMT-212","TMT212","Tmt212","Trametinib"],"crossReferences":{"PubChem":["137276024"],"drugbank":["DB08911"],"chEBI":["75998"]},"linkedTargets":{"rows":["ENSG00000126934","ENSG00000169032"],"count":2},"linkedDiseases":{"rows":["EFO_0000365","MONDO_0100342","EFO_1000849","EFO_0000756","EFO_0000571","MONDO_0000473","MONDO_0007254","EFO_1000926","EFO_1000657","EFO_0000305","EFO_1001951","EFO_0000565","MONDO_0001056","EFO_1001480","EFO_1000044","MONDO_0002974","EFO_0000389","MONDO_0008903","EFO_0000182","EFO_0000501","EFO_0000196","EFO_0000641","Orphanet_2495","MONDO_0004976","EFO_0002617","EFO_0000616","EFO_0002618","EFO_1000616","MONDO_0002108","Orphanet_44890","MONDO_0015523","EFO_0000222","EFO_1001968","EFO_0003060","EFO_0005221","MONDO_0008315","EFO_0000311","EFO_0006772","MONDO_0021639","EFO_0003868","EFO_0001378","HP_0100727","MONDO_0024880","MONDO_0021637","MONDO_0017795"],"count":45},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for cancer and neoplasm and has 36 investigational indications."}
{"id":"CHEMBL2104314","canonicalSmiles":"CCC(C)OC(=O)N1CCCCC1CCO","inchiKey":"QLHULAHOXSSASE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ICARIDIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Icaridin","Picaridin"],"crossReferences":{"PubChem":["144211458"],"drugbank":["DB14074"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2104734","canonicalSmiles":"CC(CN(C)C)CN1c2ccccc2S(=O)(=O)c2ccccc21","inchiKey":"QTQPVLDZQVPLGV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXOMEMAZINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["6487-RP","6847-RP","Doxergan","Dysedon","Exe-top","Imakol","Oplex","Oxomemazine","RP 6847","RP-6847","Trimeprazine 5,5-dioxide"],"crossReferences":{"drugbank":["DB13820"]},"childChemblIds":["CHEMBL3187201"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2106556","canonicalSmiles":"CCC1(C2=CCCCC2)C(=O)[N-]C(=O)NC1=O.CCC1(C2=CCCCC2)C(=O)[N-]C(=O)NC1=O.[Ca+2]","inchiKey":"LQOCSNZFBLPUID-UHFFFAOYSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"CYCLOBARBITAL CALCIUM","maximumClinicalTrialPhase":4,"parentId":"CHEMBL268164","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["Norway"],"classes":["Misuse"],"year":1980},"tradeNames":["Phanodorm","Phanodorn calcium"],"synonyms":["Cyclobarbital calcium","Cyclobarbital calcium salt"],"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in Norway  in 1980 due to Misuse."}
{"id":"CHEMBL2107014","canonicalSmiles":"O=C(Oc1ccc2c(c1)CCCN2C(=O)C(Cl)Cl)c1ccco1","inchiKey":"SBJGFIXQRZOVTO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"QUINFAMIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Amenide"],"synonyms":["Quinfamide","WIN 40014","WIN-40014"],"crossReferences":{"drugbank":["DB12780"]},"description":"Small molecule drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL2107062","canonicalSmiles":"CCC(C(=O)NC(N)=O)c1ccccc1","inchiKey":"AJOQSQHYDOFIOX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENETURIDE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Laburide"],"synonyms":["Acetylpheneturide","Benuride","Dl-pheneturide","Ethylphenacemide","Lircapyl","M-551","Pheneturide","Phenuride"],"crossReferences":{"PubChem":["144206203","144212525"],"drugbank":["DB13362"],"chEBI":["31989"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for epilepsy."}
{"id":"CHEMBL2107886","drugType":"Oligosaccharide","blackBoxWarning":false,"name":"REVIPARIN SODIUM","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Clivarine"],"synonyms":["Clivarin","LU-47311","Reviparin","Reviparin sodium"],"description":"Oligosaccharide drug with a maximum clinical trial phase of IV and is indicated for recurrent thrombophlebitis."}
{"id":"CHEMBL2107951","drugType":"Unknown","blackBoxWarning":false,"name":"MALTODEXTRIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fortical","Leppin","Polycal"],"synonyms":["Dextri-maltose","Glucidex","Glucodry","Maldex","Maldrin","Maltodextrin","Star-dri"],"description":"Unknown drug with a maximum clinical trial phase of IV (across all indications) and has 25 investigational indications."}
{"id":"CHEMBL2108214","drugType":"Enzyme","blackBoxWarning":false,"name":"AGALSIDASE ALFA","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Replagal"],"synonyms":[".alpha.-d-galactopyranosidase",".alpha.-d-galactosidase","Agalsidase alfa","Agalsidase alfa (genetical recombination)","Alpha-galactisidase","DRX-005B","DRX005B","EC 3.2.1.22","Melibiase"],"crossReferences":{"DrugCentral":["5021"]},"description":"Enzyme drug with a maximum clinical trial phase of IV and has 1 investigational indication."}
{"id":"CHEMBL2108726","drugType":"Protein","blackBoxWarning":false,"name":"TECHNETIUM TC 99M TILMANOCEPT","yearOfFirstApproval":2013,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Lymphoseek","Lymphoseek kit"],"synonyms":["1600","Technetium (99mtc) tilmanocept","Technetium tc 99m tilmanocept","Technetium tc-99m tilmanocept"],"crossReferences":{"DrugCentral":["4755"]},"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2013 and is indicated for breast cancer and squamous cell carcinoma and has 4 investigational indications."}
{"id":"CHEMBL2108835","drugType":"Unknown","blackBoxWarning":false,"name":"ABETIMUS SODIUM","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Abetimus sodium","LJP 394","LJP-394"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2109442","drugType":"Antibody","blackBoxWarning":false,"name":"PRO-542","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PRO-542","Pro-542"],"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2109504","drugType":"Antibody","blackBoxWarning":false,"name":"CMD-193","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CMD-193","Cmd-193"],"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2111097","canonicalSmiles":"CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@@H]1c1ccccc1Cl","inchiKey":"HTIQEAQVCYTUBX-KRWDZBQOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LEVAMLODIPINE","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Amlodipine, (s)-","Levamlodipine","S-amlodipine"],"crossReferences":{"DailyMed":["levamlodipine%20maleate"],"drugbank":["DB09237"],"chEBI":["53796"]},"childChemblIds":["CHEMBL2107350","CHEMBL4594288"],"linkedTargets":{"rows":["ENSG00000157388","ENSG00000081248","ENSG00000151067","ENSG00000102001"],"count":4},"linkedDiseases":{"rows":["MONDO_0001134","EFO_0000537"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for hypertension and has 2 investigational indications."}
{"id":"CHEMBL2111290","drugType":"Protein","blackBoxWarning":false,"name":"TESAMORELIN ACETATE","yearOfFirstApproval":2010,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1237026","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Egrifta"],"synonyms":["TH9507","Tesamorelin acetate"],"linkedTargets":{"rows":["ENSG00000106128"],"count":1},"linkedDiseases":{"rows":["EFO_1001348"],"count":1},"description":"Protein drug with a maximum clinical trial phase of IV that was first approved in 2010 and is indicated for hiv-associated lipodystrophy syndrome."}
{"id":"CHEMBL214332","canonicalSmiles":"CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(N)=O)C(C)C","inchiKey":"WHNFPRLDDSXQCL-UAZQEYIDSA-N","drugType":"Protein","blackBoxWarning":false,"name":"INTERMEDINE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[".alpha.-melanotropin",".alpha.-melanotropin (human)",".alpha.-melanotropin (ox)",".alpha.-melanotropin (sheep)",".alpha.-msh","Alpha-melanocyte stimulating hormone","Alpha-msh","Intermedin","Intermedine","Melanophore-stimulating hormone","Melanotropin","Melanotropin alpha","Melantropin","N-acetyl-acth(1-13)-amide"],"crossReferences":{"Wikipedia":["Melanocyte-stimulating_hormone"]},"description":"Protein drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2151205","canonicalSmiles":"COc1nc(/C=C/c2nc3n(n2)CCC[C@H]3c2ccccc2C(F)(F)F)ccc1-n1cnc(C)c1","inchiKey":"SSGLBUGNISHUAO-RDELFYGPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"E-2212","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["E-2212","E2212"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL218166","canonicalSmiles":"O=c1[nH]c2cccc(N3CCN(Cc4cccc(-c5ccccc5)c4)CC3)c2o1","inchiKey":"CYGODHVAJQTCBG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BIFEPRUNOX","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bifeprunox"],"crossReferences":{"Wikipedia":["Bifeprunox"],"drugbank":["DB04888"]},"childChemblIds":["CHEMBL2107317"],"linkedTargets":{"rows":["ENSG00000178394","ENSG00000149295"],"count":2},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0000289","MONDO_0002050","MONDO_0004975","EFO_0009963","EFO_0005411"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 6 investigational indications."}
{"id":"CHEMBL219916","canonicalSmiles":"O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1","inchiKey":"FGXWKSZFVQUSTL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DOMPERIDONE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Domilium","Evoxin","Motilium","Motilium 10","Motilium instants","Vivadone"],"synonyms":["Domperidone","NSC-299589","NSC-759575","R 33,812","R-33812"],"crossReferences":{"PubChem":["11111029","124878657","124878660","124878661","124878664","144203607","147912","170465594","174006911","26746912","26746913","26751449","4254117","46500486","50103922","50103923","50103924","50103925","50109475","85230869","855562","90341791"],"Wikipedia":["Domperidone"],"drugbank":["DB01184"],"chEBI":["31515"]},"childChemblIds":["CHEMBL4594380","CHEMBL3436365"],"linkedTargets":{"rows":["ENSG00000149295"],"count":1},"linkedDiseases":{"rows":["EFO_0003948","EFO_1001463","EFO_0003840","EFO_0010282","MONDO_0005180","EFO_0003929","EFO_1000948","EFO_0003917","EFO_0008533"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for gastrointestinal disease and has 9 investigational indications."}
{"id":"CHEMBL22055","canonicalSmiles":"CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)Cc2ccccc2)c(=O)n(-c2ccccc2)c(=O)n3Cc2c(F)cccc2F)cc1","inchiKey":"UCQSBGOFELXYIN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SUFUGOLIX","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Sufugolix","TAK-013","Tak-013"],"crossReferences":{"drugbank":["DB06494"]},"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL2387080","canonicalSmiles":"Cc1nc(-c2cn3c(n2)-c2ccc(-c4cnn(C(C)(C)C(N)=O)c4)cc2OCC3)n(C(C)C)n1","inchiKey":"BEUQXVWXFDOSAQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TASELISIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GDC-0032","RG-7604","Taselisib"],"crossReferences":{"drugbank":["DB12108"]},"linkedTargets":{"rows":["ENSG00000145675","ENSG00000171608","ENSG00000105647","ENSG00000141506","ENSG00000051382","ENSG00000121879","ENSG00000105851","ENSG00000117461"],"count":8},"linkedDiseases":{"rows":["MONDO_0007254","EFO_0009146","EFO_0001378","EFO_0000708","EFO_0005952","EFO_0000305"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL269671","canonicalSmiles":"C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4","inchiKey":"BLUAFEHZUWYNDE-NNWCWBAJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL269671","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["49720288"],"drugbank":["DB13132"],"chEBI":["223316"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL302213","canonicalSmiles":"NC[C@@H](CC(=O)O)c1ccc(Cl)cc1","inchiKey":"KPYSYYIEGFHWSV-MRVPVSSYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL302213","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["11110851","11112470","11113490","124879421"],"drugbank":["DB12098"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL309499","canonicalSmiles":"N=C(N)NO","inchiKey":"WFBHRSAKANVBKH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HYDROXYGUANIDINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(Diaminomethylene)(Hydroxy)Ammonium Hydrogen Sulfate","Hydroxyguanidine"],"crossReferences":{"drugbank":["DB03770"],"chEBI":["43089"]},"childChemblIds":["CHEMBL1160506"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL313006","canonicalSmiles":"CCC(CC)CC1(C(=O)Nc2ccccc2SC(=O)C(C)C)CCCCC1","inchiKey":"YZQLWPMZQVHJED-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DALCETRAPIB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dalcetrapib","JTT-705","RO-4607381","RO4607381"],"crossReferences":{"Wikipedia":["Dalcetrapib"],"drugbank":["DB12181"]},"linkedTargets":{"rows":["ENSG00000087237"],"count":1},"linkedDiseases":{"rows":["MONDO_0100096","MONDO_0021187","EFO_0001645","HP_0003119","EFO_0000319","EFO_0005672","Orphanet_309005","EFO_0004265"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL31421","canonicalSmiles":"CC1(C)SSC(C)(C)[C@@H](NC(=O)[C@@H](N)Cc2ccc(O)cc2)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H]1C(=O)O","inchiKey":"MCMMCRYPQBNCPH-WMIMKTLMSA-N","drugType":"Protein","blackBoxWarning":false,"name":"CHEMBL31421","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08861"],"chEBI":["73356"]},"description":"Protein drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3182343","canonicalSmiles":"CC(C)(C)C(=O)OCOC(=O)[C@@H]1N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1(C)C","inchiKey":"ZEMIJUDPLILVNQ-ZXFNITATSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIVAMPICILLIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Pondocillin"],"synonyms":["MK-191","Pivampicillin"],"crossReferences":{"PubChem":["144204182","170466065"],"drugbank":["DB01604"],"chEBI":["8255"]},"childChemblIds":["CHEMBL3989412","CHEMBL3989898"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for bacterial disease."}
{"id":"CHEMBL331858","canonicalSmiles":"COc1cccc(N2CCc3cc(S(N)(=O)=O)sc3S2(=O)=O)c1","inchiKey":"ICIXQGGQPKFQRL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AL-7182","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AL-7182"],"crossReferences":{"drugbank":["DB02602"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL336712","canonicalSmiles":"CN1CCN2c3ccccc3Cn3cccc3C2C1","inchiKey":"MNHDDERDSNZCCK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"APTAZAPINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aptazapine"],"crossReferences":{"Wikipedia":["Aptazapine"],"drugbank":["DB09305"]},"childChemblIds":["CHEMBL2106459"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3544974","canonicalSmiles":"CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\\C(=O)O","inchiKey":"GMDCDXMAFMEDAG-BTJKTKAUSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"ASENAPINE MALEATE","yearOfFirstApproval":2009,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL3187365","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Saphris"],"synonyms":["Asenapine (as maleate)","Asenapine maleate","ORG 5222","ORG-5222"],"crossReferences":{"DailyMed":["asenapine%20maleate"],"drugbank":["DB06216"]},"linkedTargets":{"rows":["ENSG00000149295","ENSG00000102468"],"count":2},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0000289","MONDO_0002009","EFO_0000677","EFO_0009963","EFO_0005407","EFO_0001358","EFO_0005411","HP_0000713"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2009 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL3545004","drugType":"Small molecule","blackBoxWarning":false,"name":"PL-225B","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pl-225b"],"linkedTargets":{"rows":["ENSG00000140443"],"count":1},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545071","drugType":"Antibody","blackBoxWarning":false,"name":"SERIBANTUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MM121","SAR256212","Seribantumab"],"linkedTargets":{"rows":["ENSG00000065361"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","MONDO_0007254"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3545085","canonicalSmiles":"CC(C)c1cc(CNc2nc(Nc3cc(C4CC4)[nH]n3)cc(N3CCN(C)CC3)n2)on1","inchiKey":"ALKJNCZNEOTEMP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"XL-228","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Exel-2280","XL228","Xl-228"],"linkedTargets":{"rows":["ENSG00000101336","ENSG00000000938","ENSG00000182866","ENSG00000097007","ENSG00000254087","ENSG00000125508","ENSG00000140443","ENSG00000111816","ENSG00000176105","ENSG00000136573","ENSG00000010810","ENSG00000197122"],"count":12},"linkedDiseases":{"rows":["EFO_0000339","EFO_0000220","EFO_0000574","EFO_0000311"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL3545133","drugType":"Small molecule","blackBoxWarning":false,"name":"JNJ-26483327","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["JNJ 26483327","JNJ-26483327","Jnj-26483327"],"linkedTargets":{"rows":["ENSG00000146648","ENSG00000182866","ENSG00000037280","ENSG00000254087","ENSG00000178568","ENSG00000176105","ENSG00000141736","ENSG00000010810","ENSG00000197122"],"count":9},"linkedDiseases":{"rows":["EFO_0000311"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545249","drugType":"Small molecule","blackBoxWarning":false,"name":"GLPG-0555","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Glpg-0555"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545298","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD-6918","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Azd-6918"],"linkedTargets":{"rows":["ENSG00000140538","ENSG00000148053","ENSG00000198400"],"count":3},"linkedDiseases":{"rows":["EFO_0000311"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3561663","canonicalSmiles":"CCCCCCCCCCCC(=O)Cl","inchiKey":"NQGIJDNPUZEBRU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3561663","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["251919787"],"drugbank":["DB14670"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3707319","drugType":"Small molecule","blackBoxWarning":false,"name":"GRC-15300","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Grc-15300","SAR-292833"],"linkedTargets":{"rows":["ENSG00000167723"],"count":1},"linkedDiseases":{"rows":["EFO_0005762"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3824393","canonicalSmiles":"C[N+](C)(C)CCCOc1ccc(-c2c3nc(cc4ccc([nH]4)c(-c4ccc(OCCC[N+](C)(C)C)cc4)c4nc(cc5ccc2[nH]5)C=C4)C=C3)cc1","inchiKey":"KZTXNPVFWHWJSH-OPFFBBNOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EXEPORFINIUM","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Exeporfinium cation","Exeporfinium ion"],"childChemblIds":["CHEMBL3822503"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3833308","drugType":"Antibody","blackBoxWarning":false,"name":"BIIB059","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BIIB059","Biib059"],"linkedTargets":{"rows":["ENSG00000198178"],"count":1},"linkedDiseases":{"rows":["EFO_0003834","EFO_0002690"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3833411","canonicalSmiles":"OB1OB2OB(O)OB(O1)O2","inchiKey":"XDVOLDOITVSJGL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BORATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL3833375"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL383899","canonicalSmiles":"O=C(Nc1cccc(Nc2nccc(Nc3cccc(C(F)(F)F)c3)n2)c1)C1CC1","inchiKey":"RDTDWGQDFJPTPD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ANILINOPYRIMIDINE1","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Anilinopyrimidine1"],"crossReferences":{"drugbank":["DB07545"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL38851","canonicalSmiles":"N#Cc1ccc(-c2ccc(OCCC(=O)NO)cc2)cc1","inchiKey":"XZWFHJUEAVOHHG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL38851","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08030"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3940890","canonicalSmiles":"Cc1n[nH]c(C)c1CCCOc1cc(C(=O)O)ccc1F","inchiKey":"WBFUHHBPNXWNCC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ACORAMIDIS","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AG-10","AG10","Acoramidis","Ag10"],"childChemblIds":["CHEMBL4650226"],"linkedTargets":{"rows":["ENSG00000118271"],"count":1},"linkedDiseases":{"rows":["EFO_1001984","EFO_1001875","Orphanet_85447","Orphanet_85451"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3984425","canonicalSmiles":"C[C@H](NC(=O)c1c(N)nn2cccnc12)c1cc2cccc(C#Cc3cnn(C)c3)c2c(=O)n1-c1ccccc1","inchiKey":"XUMALORDVCFWKV-IBGZPJMESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EGANELISIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Eganelisib","IPI-549","Ipi-549","Pi3k-gamma inhibitor ipi-549"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL3989968","canonicalSmiles":"CCOc1ccccc1C(=O)NCc1coc(-c2ccc(OC(F)F)c(OC(C)C)c2)n1","inchiKey":"VFBILHPIHUPBPZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIFAMILAST","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Difamilast","OPA-15406"],"crossReferences":{"drugbank":["DB14987"]},"linkedTargets":{"rows":["ENSG00000065989","ENSG00000105650","ENSG00000113448","ENSG00000184588"],"count":4},"linkedDiseases":{"rows":["EFO_0000274"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL401365","canonicalSmiles":"CCOc1ccc(OCC)c(NC(=O)c2cc(C)c(OCCN)c(C)c2)c1","inchiKey":"PHTPPZCTHZHCQD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL401365","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07625"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL403","canonicalSmiles":"CC1(C)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O","inchiKey":"FKENQMMABCRJMK-RITPCOANSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULBACTAM","yearOfFirstApproval":1986,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["CP-45899","CP-458992","NSC-759886","Sulbactam"],"crossReferences":{"DailyMed":["sulbactam%20sodium"],"PubChem":["144207191","170465248","47193857"],"Wikipedia":["Sulbactam"],"drugbank":["DB09324"],"chEBI":["9321"]},"childChemblIds":["CHEMBL3989650","CHEMBL1200944"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1986 and is indicated for infection and bacterial disease and has 7 investigational indications."}
{"id":"CHEMBL4073796","canonicalSmiles":"O=S(=O)(O)O[C@H]1[C@H](O)CO[C@@H](O[C@@H]2CO[C@@H](O)[C@H](OS(=O)(=O)O)[C@H]2OS(=O)(=O)O)[C@@H]1OS(=O)(=O)O","inchiKey":"FCCNSUIJIOOXEZ-SJYYZXOBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL4073796","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB00686"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4074884","canonicalSmiles":"COC1=C(OC)C(=O)C(CCCCCCCCCC[P+](c2ccccc2)(c2ccccc2)c2ccccc2)=C(C)C1=O.CS(=O)(=O)[O-]","inchiKey":"GVZFUVXPTPGOQT-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"MITOQUINONE MESYLATE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL1229093","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mitoq","Mitoquinone mesylate","Mitoquinone methanesulfonate"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL418875","canonicalSmiles":"O=C(O)CCNC(=O)[C@H]1CCCN1S(=O)(=O)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1","inchiKey":"SRAHBOKVSSZEHQ-LSDHHAIUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL418875","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03558"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL427","canonicalSmiles":"CN(CCCl)CCCl","inchiKey":"HAWPXGHAZFHHAD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MECHLORETHAMINE","yearOfFirstApproval":1949,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Chlorethazine","Chlormethine","Mechlorethamine","Mustargen","NSC-10107","NSC-128663","NSC-757087","Nitrogen mustard (hn 2)"],"crossReferences":{"DailyMed":["mechlorethamine%20hydrochloride"],"PubChem":["174007395","26747396"],"Wikipedia":["Mechlorethamine"],"drugbank":["DB00888"],"chEBI":["28925"]},"childChemblIds":["CHEMBL1201001"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1949 and is indicated for neoplasm and cutaneous t-cell lymphoma and has 5 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL4290141","canonicalSmiles":"CC1(C)CC(Oc2ccc(-c3ccc(-c4cn[nH]c4)cc3O)nn2)CC(C)(C)N1","inchiKey":"STWTUEAWRAIWJG-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BRANAPLAM","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Branaplam","LMI-070","LMI070","Nvs-sm1"],"crossReferences":{"drugbank":["DB14918"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297326","canonicalSmiles":"COc1cccc(C(=O)Nc2ccc3c(c2)CCN(C(=O)Oc2ccccc2)C3)c1-c1ccc(C(F)(F)F)cc1","inchiKey":"AZUIUVJESCFSLJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SLX-4090","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["KD-026","Slx-4090"],"crossReferences":{"drugbank":["DB05678"]},"linkedTargets":{"rows":["ENSG00000138823","ENSG00000185624"],"count":2},"linkedDiseases":{"rows":["EFO_0004211","MONDO_0021187","Orphanet_411","MONDO_0005148"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297350","canonicalSmiles":"C[C@H](Oc1ccc(-c2nc(-c3ccc4[nH]cnc4c3)no2)cc1C(F)(F)F)C(F)(F)F","inchiKey":"NJNXCJPSMWKXHO-VIFPVBQESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ASP-4058","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ASP4058","Asp-4058","Asp4058"],"crossReferences":{"drugbank":["DB11819"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297681","drugType":"Unknown","blackBoxWarning":false,"name":"AB-101","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AB-101","AB101","Ab-101","Insular"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297741","drugType":"Unknown","blackBoxWarning":false,"name":"DASIGLUCAGON","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dasiglucagon","ZP-4207","ZP-GA-1","ZP4207"],"linkedTargets":{"rows":["ENSG00000215644"],"count":1},"linkedDiseases":{"rows":["MONDO_0005147","Orphanet_657","HP_0001943","EFO_0007318"],"count":4},"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297762","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"GOLODIRSEN","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Vyondys 53"],"synonyms":["Golodirsen","NG-12-0163","SRP-4053"],"crossReferences":{"DailyMed":["golodirsen"]},"linkedTargets":{"rows":["ENSG00000198947"],"count":1},"linkedDiseases":{"rows":["Orphanet_98896","Orphanet_98473"],"count":2},"description":"Oligonucleotide drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated for muscular dystrophy and duchenne muscular dystrophy."}
{"id":"CHEMBL4297810","drugType":"Unknown","blackBoxWarning":false,"name":"PI-0824","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Pi-0824"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297820","drugType":"Antibody","blackBoxWarning":false,"name":"ROZANOLIXIZUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Rozanolixizumab","UCB-7665","UCB7665","Ucb7665"],"linkedTargets":{"rows":["ENSG00000104870"],"count":1},"linkedDiseases":{"rows":["EFO_0007160","EFO_1000868","EFO_0004991","HP_0001873"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4298022","drugType":"Unknown","blackBoxWarning":false,"name":"LY-3321367","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LY-3321367","LY3321367","Ly 3321367","Ly-3321367","Ly3321367"],"description":"Unknown drug with a maximum clinical trial phase of I (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4298049","drugType":"Unknown","blackBoxWarning":false,"name":"MS-1819","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Adrulipase alfa","Lipase 2 (yarrowia lipolytica)","MS-1819","MS1819","MS1819-SD","Ms-1819","Ms1819-sd"],"description":"Unknown drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4298050","drugType":"Antibody","blackBoxWarning":false,"name":"TIRAGOLUMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MTIG-7192A","MTIG7192A","Mtig 7192a","Mtig7192a","RG-6058","RG6058","RO-7092284","RO7092284","Tiragolumab"],"linkedTargets":{"rows":["ENSG00000181847"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0005922","EFO_0002916","EFO_0000503","EFO_0000756","EFO_1000657","MONDO_0007576","EFO_1001513","EFO_0003060","EFO_0000311","MONDO_0001187","EFO_1001480","EFO_1000044","MONDO_0002974","EFO_0005537","EFO_0000389","MONDO_0011962","EFO_0000702","EFO_0008528","MONDO_0003219","EFO_0000181"],"count":21},"description":"Antibody drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."}
{"id":"CHEMBL4298089","drugType":"Antibody","blackBoxWarning":false,"name":"CODRITUZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Codrituzumab","GC-33","GC33","RO5137382","Ro5137382"],"linkedTargets":{"rows":["ENSG00000147257"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000182"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4298162","canonicalSmiles":"CC1(C)C(/C=C/C2=C(Oc3ccc(S(=O)(=O)O)cc3)/C(=C/C=C3/N(CCCCS(=O)(=O)O)c4ccc(S(=O)(=O)O)cc4C3(C)C)CCC2)=[N+](CCCCS(=O)(=O)[O-])c2ccc(S(=O)(=O)O)cc21","inchiKey":"FRMYEKPWHJAHIO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NERINDOCIANINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["830-15455","IRDye 800BK","Nerindocianine"],"childChemblIds":["CHEMBL4298163"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4303545","canonicalSmiles":"COc1ccc(S(=O)(=O)N2CCCN(S(=O)(=O)c3ccc(OC)c(OC)c3)CC2)cc1OC","inchiKey":"GJUFPAZNBPFNRI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SB-756050","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SB-050","Sb-756050"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL43128","canonicalSmiles":"COc1cc(NC(C)CCCN)c2ncccc2c1.O=P(O)(O)O.O=P(O)(O)O","inchiKey":"GJOHLWZHWQUKAU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PRIMAQUINE PHOSPHATE","yearOfFirstApproval":1952,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL506","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Primaquine","Primaquine phosphate"],"synonyms":["Malquine","NSC-149765","Primachine phosphate","Primaquine Phosphate","Primaquine diphosphate","Primaquine phosphate","Primaquini diphosphas","WR 2975"],"crossReferences":{"DailyMed":["primaquine%20phosphate"],"PubChem":["144203901","170465072","26748220"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1952 and has 4 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL443455","canonicalSmiles":"CC(=O)NC(=O)N[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O","inchiKey":"UQKBNLXZEGBQAF-JAJWTYFOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL443455","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03218"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4471306","canonicalSmiles":"C[C@H](Nc1cc(Cl)nc2c1cnn2[C@@H]1O[C@H](COP(=O)(O)CP(=O)(O)O)[C@@H](O)[C@H]1O)c1ccccc1F","inchiKey":"MFYLCAMJNGIULC-KCVUFLITSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"QUEMLICLUSTAT","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AB-680","AB680","Ab680","Quemliclustat"],"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL451930","canonicalSmiles":"CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O","inchiKey":"UUSZLLQJYRSZIS-LXNNNBEUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PLITIDEPSIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aplidin","Aplidine","Plitidepsin"],"crossReferences":{"drugbank":["DB04977"],"chEBI":["90205"]},"linkedTargets":{"rows":["ENSG00000101210"],"count":1},"linkedDiseases":{"rows":["EFO_0000565","EFO_0000616","MONDO_0044903","MONDO_0100096","EFO_0000574","EFO_0001378","MONDO_0008315","EFO_0003085"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL4594385","drugType":"Antibody","blackBoxWarning":false,"name":"ASTEGOLIMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG-282","AMG282","Astegolimab","MSTT-1041A","MSTT1041A","Mstt1041a","RG-6149","RG6149","RO-7187807"],"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4594544","drugType":"Antibody","blackBoxWarning":false,"name":"BEXMARILIMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bexmarilimab","Clevegen","FP-1305","Fp-1305"],"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL463480","canonicalSmiles":"O=c1cnn([C@@H]2O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1","inchiKey":"LRVZOSYMNMNQFR-SHUUEZRQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"6-AZA-URIDINE MONOPHOSPHATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["6-Aza-UMP","6-Aza-Uridine Monophosphate"],"crossReferences":{"drugbank":["DB03718"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4649457","canonicalSmiles":"COc1ccccc1CC[C@@H]1CCc2cc([C@H]3CC[C@](N)(CO)C3)ccc2C1","inchiKey":"QCMHGCDOZLWPOT-FMNCTDSISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BMS-986166","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BMS-986166","Bms-986166"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4650492","drugType":"Antibody","blackBoxWarning":false,"name":"UNASNEMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MT-3921","MT3921","Mt-3921","Unasnemab"],"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4650507","drugType":"Protein","blackBoxWarning":false,"name":"RUSFERTIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PTG-300","PTG-300FB","Ptg-300","Rusfertide"],"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4802178","drugType":"Unknown","blackBoxWarning":false,"name":"PF-04603629","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BRX-1177","BRX1177","Pf-04603629"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL490029","canonicalSmiles":"CC[C@@H](Oc1cccc(-n2c(C)c(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O","inchiKey":"STWITCBWQHTJFJ-XMMPIXPASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MK-0533","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MK-0533","MK0533","Mk-0533"],"crossReferences":{"drugbank":["DB15242"]},"linkedTargets":{"rows":["ENSG00000132170"],"count":1},"linkedDiseases":{"rows":["MONDO_0005148"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL531","canonicalSmiles":"CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21","inchiKey":"YEHCICAEULNIGD-MZMPZRCHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PERGOLIDE","yearOfFirstApproval":1988,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"classes":["Cardiotoxicity"],"year":2007},"tradeNames":[],"synonyms":["Pergolide"],"crossReferences":{"PubChem":["104171354","26754330","26754331","90341767"],"Wikipedia":["Pergolide"],"drugbank":["DB01186"],"chEBI":["63617"]},"childChemblIds":["CHEMBL1275"],"linkedTargets":{"rows":["ENSG00000184845","ENSG00000069696","ENSG00000149295","ENSG00000151577","ENSG00000169676"],"count":5},"linkedDiseases":{"rows":["EFO_0002610","MONDO_0005180"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1988 and is indicated for parkinson disease and has 1 investigational indication. It was withdrawn in United States  in 2007 due to Cardiotoxicity."}
{"id":"CHEMBL560993","canonicalSmiles":"Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O","inchiKey":"FATGTHLOZSXOBC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OC000459","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["OC-000459","OC000459","OC459","Oc-459","Oc000459","Timapiprant"],"crossReferences":{"drugbank":["DB11900"]},"linkedTargets":{"rows":["ENSG00000183134"],"count":1},"linkedDiseases":{"rows":["EFO_0004232","EFO_0005854","MONDO_0004979","EFO_0000274"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL57004","canonicalSmiles":"CCN(CC)CCCCCCNc1cc(OC)cc2c(C)ccnc12","inchiKey":"RVAKDGYPIVSYEU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SITAMAQUINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Sitamaquine","WR 6026"],"crossReferences":{"drugbank":["DB04909"]},"childChemblIds":["CHEMBL4544369","CHEMBL3216296","CHEMBL3142235"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL60889","canonicalSmiles":"CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1","inchiKey":"YPELFRMCRYSPKZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MOSAPRIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Mosapride","Mosart"],"crossReferences":{"PubChem":["174006284","29216210","50110109"],"Wikipedia":["Mosapride"],"drugbank":["DB11675"]},"childChemblIds":["CHEMBL1733174"],"linkedTargets":{"rows":["ENSG00000164270","ENSG00000149305","ENSG00000186090","ENSG00000178084","ENSG00000186038","ENSG00000166736"],"count":6},"linkedDiseases":{"rows":["EFO_0000217","EFO_0010282","EFO_0000555","HP_0002014","MONDO_0021392","MONDO_0004567","EFO_1000948","MONDO_0005148","HP_0002019","EFO_0008533"],"count":10},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL623","canonicalSmiles":"CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1","inchiKey":"VRBKIVRKKCLPHA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"NEFAZODONE","yearOfFirstApproval":1994,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Nefazodone"],"crossReferences":{"DailyMed":["nefazodone%20hydrochloride"],"PubChem":["29217604","49666410","50111710"],"Wikipedia":["Nefazodone"],"drugbank":["DB01149"],"chEBI":["7494"]},"childChemblIds":["CHEMBL1200492"],"linkedTargets":{"rows":["ENSG00000108576","ENSG00000103546","ENSG00000102468","ENSG00000147246"],"count":4},"linkedDiseases":{"rows":["EFO_0007191","EFO_0002610","MONDO_0002009","EFO_0003761","EFO_0005230"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1994 and is indicated for unipolar depression and major depressive disorder and has 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL65794","canonicalSmiles":"CO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3cccc4c3CCC4)CS[C@H]12)c1csc(N)n1","inchiKey":"DKOQGJHPHLTOJR-WHRDSVKCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFPIROME","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Cefir","Cefpirome","HR-810 FREE BASE"],"crossReferences":{"PubChem":["50125933"],"drugbank":["DB13682"],"chEBI":["3503"]},"childChemblIds":["CHEMBL2106076"],"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for bacterial disease."}
{"id":"CHEMBL697","canonicalSmiles":"CN1C(=O)CC(C)(c2ccccc2)C1=O","inchiKey":"AJXPJJZHWIXJCJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METHSUXIMIDE","yearOfFirstApproval":1957,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Celontin"],"synonyms":["Mesuximide","Methsuximide","NSC-760075"],"crossReferences":{"DailyMed":["methsuximide"],"PubChem":["144207162"],"Wikipedia":["Mesuximide"],"drugbank":["DB05246"]},"linkedTargets":{"rows":["ENSG00000100346","ENSG00000006283","ENSG00000196557"],"count":3},"linkedDiseases":{"rows":["EFO_0000474","HP_0001250"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1957 and is indicated for seizure and epilepsy."}
{"id":"CHEMBL7257","canonicalSmiles":"COc1ccc2[nH]cc(CCN(C)C)c2c1","inchiKey":"ZSTKHSQDNIGFLM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"5-MEO-DMT","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["5-OME-DMT","[2-(5-Methoxy-1H-Indol-3-Yl)-Ethyl]-Dimethyl-Amine"],"crossReferences":{"PubChem":["11111436","26751543","50100273","50104133","855873"],"Wikipedia":["5-MeO-DMT"],"drugbank":["DB14010"],"chEBI":["2086"]},"childChemblIds":["CHEMBL1256920"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL765","canonicalSmiles":"NC(N)=NCCN1CCCCCCC1","inchiKey":"ACGDKVXYNVEAGU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GUANETHIDINE","yearOfFirstApproval":1960,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Esimil","Guanethidine","Ismelin"],"crossReferences":{"PubChem":["11112157"],"Wikipedia":["Guanethidine"],"drugbank":["DB01170"],"chEBI":["5557"]},"childChemblIds":["CHEMBL2051958","CHEMBL1345","CHEMBL3560112"],"linkedTargets":{"rows":["ENSG00000103546"],"count":1},"linkedDiseases":{"rows":["EFO_0000516","EFO_0000537"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and is indicated for hypertension and glaucoma."}
{"id":"CHEMBL87563","canonicalSmiles":"CCOC(=O)c1ccc(OC(=O)CCCCCN=C(N)N)cc1","inchiKey":"YKGYIDJEEQRWQH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GABEXATE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Gabexate","Gabexate mesilate"],"crossReferences":{"PubChem":["11114218"],"Wikipedia":["Gabexate"],"drugbank":["DB12831"]},"childChemblIds":["CHEMBL1398351"],"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL970","canonicalSmiles":"O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC(F)(F)F","inchiKey":"WYCLKVQLVUQKNZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HALAZEPAM","yearOfFirstApproval":1981,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Paxipam"],"synonyms":["Halazepam","Halazepam civ","SCH 12041","SCH-12041"],"crossReferences":{"Wikipedia":["Halazepam"],"drugbank":["DB00801"]},"linkedTargets":{"rows":["ENSG00000182256","ENSG00000022355","ENSG00000011677","ENSG00000113327","ENSG00000163285","ENSG00000151834","ENSG00000186297"],"count":7},"linkedDiseases":{"rows":["EFO_0005230"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1981 and is indicated for anxiety."}
